Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report

INTRODUCTION: In the phase 3 study involving the use of durvalumab with or without tremelimumab in combination with platinum-based chemotherapy in untreated extensive-stage SCLC (CASPIAN study), first-line durvalumab plus platinum-etoposide (EP) significantly improved overall survival (OS) versus EP...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yuanbin, Paz-Ares, Luis, Reinmuth, Niels, Garassino, Marina Chiara, Statsenko, Galina, Hochmair, Maximilian J., Özgüroğlu, Mustafa, Verderame, Francesco, Havel, Libor, Losonczy, György, Conev, Nikolay V., Hotta, Katsuyuki, Ji, Jun Ho, Spencer, Stuart, Dalvi, Tapashi, Jiang, Haiyi, Goldman, Jonathan W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204731/
https://www.ncbi.nlm.nih.gov/pubmed/35719865
http://dx.doi.org/10.1016/j.jtocrr.2022.100330

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204731/
https://www.ncbi.nlm.nih.gov/pubmed/35719865
http://dx.doi.org/10.1016/j.jtocrr.2022.100330

Ejemplares similares